Spero Therapeutics, Inc.

NasdaqGS:SPRO Stock Report

Market Cap: US$46.7m

Spero Therapeutics Past Earnings Performance

Past criteria checks 3/6

Spero Therapeutics has been growing earnings at an average annual rate of 34.1%, while the Biotechs industry saw earnings growing at 19.3% annually. Revenues have been growing at an average rate of 52.1% per year. Spero Therapeutics's return on equity is 5.4%, and it has net margins of 3.3%.

Key information

34.1%

Earnings growth rate

43.1%

EPS growth rate

Biotechs Industry Growth17.0%
Revenue growth rate52.1%
Return on equity5.4%
Net Margin3.3%
Last Earnings Update30 Sep 2024

Recent past performance updates

Recent updates

Spero Therapeutics: Undervalued Based On Just Tebipenem And GSK Deal

Jan 19

There Is A Reason Spero Therapeutics, Inc.'s (NASDAQ:SPRO) Price Is Undemanding

Nov 02
There Is A Reason Spero Therapeutics, Inc.'s (NASDAQ:SPRO) Price Is Undemanding

Insufficient Growth At Spero Therapeutics, Inc. (NASDAQ:SPRO) Hampers Share Price

Jul 15
Insufficient Growth At Spero Therapeutics, Inc. (NASDAQ:SPRO) Hampers Share Price

Spero Therapeutics Delivers On Game Plan To Create Shareholder Value

Apr 23

Spero Therapeutics, Inc. (NASDAQ:SPRO) Held Back By Insufficient Growth Even After Shares Climb 27%

Mar 12
Spero Therapeutics, Inc. (NASDAQ:SPRO) Held Back By Insufficient Growth Even After Shares Climb 27%

Spero Therapeutics, Inc.'s (NASDAQ:SPRO) Share Price Boosted 26% But Its Business Prospects Need A Lift Too

Jan 02
Spero Therapeutics, Inc.'s (NASDAQ:SPRO) Share Price Boosted 26% But Its Business Prospects Need A Lift Too

Need To Know: Analysts Just Made A Substantial Cut To Their Spero Therapeutics, Inc. (NASDAQ:SPRO) Estimates

May 18
Need To Know: Analysts Just Made A Substantial Cut To Their Spero Therapeutics, Inc. (NASDAQ:SPRO) Estimates

Spero Therapeutics, Inc. (NASDAQ:SPRO) Shares Fly 26% But Investors Aren't Buying For Growth

Apr 17
Spero Therapeutics, Inc. (NASDAQ:SPRO) Shares Fly 26% But Investors Aren't Buying For Growth

Industry Analysts Just Upgraded Their Spero Therapeutics, Inc. (NASDAQ:SPRO) Revenue Forecasts By 40%

Apr 13
Industry Analysts Just Upgraded Their Spero Therapeutics, Inc. (NASDAQ:SPRO) Revenue Forecasts By 40%

We Think Spero Therapeutics (NASDAQ:SPRO) Can Easily Afford To Drive Business Growth

Apr 05
We Think Spero Therapeutics (NASDAQ:SPRO) Can Easily Afford To Drive Business Growth

Spero Therapeutics: The GlaxoSmithKline-Deal Changes Everything And Protects Shareholder Value

Oct 03

Spero Therapeutics appoints Kamal Hamed MD CMO

Sep 15

Spero jumps 64% as FDA clarifies future regulatory path for UTI candidate

Sep 06

Spero Therapeutics GAAP EPS of -$0.87, revenue of $1.99M

Aug 10

We're A Little Worried About Spero Therapeutics' (NASDAQ:SPRO) Cash Burn Rate

Jul 04
We're A Little Worried About Spero Therapeutics' (NASDAQ:SPRO) Cash Burn Rate

Revenue & Expenses Breakdown

How Spero Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

NasdaqGS:SPRO Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 2410642333
30 Jun 2411817240
31 Mar 2411123240
31 Dec 2310423260
30 Sep 2378-22633
30 Jun 2354-10270
31 Mar 2354-27280
31 Dec 2254-46360
30 Sep 229-102430
30 Jun 2210-113480
31 Mar 2213-103490
31 Dec 2118-90420
30 Sep 2117-79360
30 Jun 2118-76300
31 Mar 2115-74260
31 Dec 209-79210
30 Sep 2011-85180
30 Jun 2012-84170
31 Mar 2012-80160
31 Dec 1918-61160
30 Sep 1916-47150
30 Jun 1912-39140
31 Mar 1911-36140
31 Dec 184-42130
30 Sep 183-46120
30 Jun 183-47120
31 Mar 183-50120
31 Dec 172-46110
30 Sep 171-40110
30 Jun 171-3590
31 Mar 170-3070
31 Dec 160-3070

Quality Earnings: SPRO has high quality earnings.

Growing Profit Margin: SPRO became profitable in the past.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: SPRO has become profitable over the past 5 years, growing earnings by 34.1% per year.

Accelerating Growth: SPRO has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.

Earnings vs Industry: SPRO has become profitable in the last year, making it difficult to compare its past year earnings growth to the Biotechs industry (20%).


Return on Equity

High ROE: SPRO's Return on Equity (5.4%) is considered low.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/02/02 04:22
End of Day Share Price 2025/01/31 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Spero Therapeutics, Inc. is covered by 9 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Esther Lannie HongBerenberg
Jason Matthew GerberryBofA Global Research
Joshua SchimmerEvercore ISI